CASKIN2 (NM_020753) Human Recombinant Protein

CAT#: TP762193

Purified recombinant protein of Human CASK interacting protein 2 (CASKIN2), transcript variant 1, Ala147-Ala552, with N-terminal His tag, expressed in E.coli, 50ug



  View other "CASKIN2" proteins (2)

Need it in bulk or customized?
Get a free quote

CNY 1,948.00


货期*
现货

规格
    • 50 ug

Product images

经常一起买 (1)
CASKIN2 mouse monoclonal antibody,clone OTI7C5
    • 100 ul

CNY 1,999.00
CNY 2,700.00

Specifications

Product Data
Species Human
Expression Host E. coli
Expression cDNA Clone or AA Sequence
A DNA sequence encoding the region(Ala147-Ala552) of CASKIN2
Tag N-His
Predicted MW 43.9 kDa
Concentration >0.05 µg/µL as determined by microplate BCA method
Purity > 80% as determined by SDS-PAGE and Coomassie blue staining
Buffer 50 mM Tris-HCl, pH 8.0, 8 M urea
Note For testing in cell culture applications, please filter before use. Note that you may experience some loss of protein during the filtration process.
Storage Store at -80°C.
Stability Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
Reference Data
RefSeq NP_065804
Locus ID 57513
UniProt ID Q8WXE0
Refseq Size 5005
Cytogenetics 17q25.1
Refseq ORF 3606
Synonyms ANKS5B
Summary This gene encodes a large protein that contains six ankyrin repeats, as well as a Src homology 3 (SH3) domain and two sterile alpha motif (SAM) domains, which may be involved in protein-protein interactions. The C-terminal portion of this protein is proline-rich and contains a conserved region. A related protein interacts with calcium/calmodulin-dependent serine protein kinase (CASK). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2013]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...